Ankylosing Spondylitis Market Size Forecast From 2026 To 2030: Key Industry Trends
Featuring market attractiveness scoring, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, deeper supply chain intelligence, emerging startup tracking, and granular product-level insights, The Business Research Company’s 2026 market reports are built to deliver research that is both more actionable and more strategically valuable.
Ankylosing Spondylitis Market Forecast: Value Set To Climb From $6.85 Billion To $9.42 Billion
The ankylosing spondylitis market has demonstrated substantial growth in recent years. It is projected to increase from $6.34 billion in 2025 to $6.85 billion in 2026, reflecting a compound annual growth rate (CAGR) of 8.0%. The expansion observed in the historic period can be ascribed to enhanced diagnostic awareness, a broader availability of NSAIDs and DMARDs, an increase in specialist rheumatology services, expanded access to hospital-based treatments, and the rising utilization of imaging for disease monitoring.
The ankylosing spondylitis market is set to experience significant expansion in the coming years. It is projected to reach $9.42 billion by 2030, driven by a compound annual growth rate (CAGR) of 8.3%. This anticipated growth throughout the forecast period stems from the increasing adoption of biologics and biosimilars, a heightened emphasis on personalized medicine, the development of advanced biologic pipelines, a rising need for long-term disease management, and increased investments in autoimmune research. Noteworthy trends during this period include the wider acceptance of biologic therapies, a surge in the use of targeted DMARDs, a greater focus on early disease diagnosis, the proliferation of personalized treatment strategies, and improved integration of physical therapy programs.
Get A Free Sample Report With In-Depth Market Insights:
Ankylosing Spondylitis Market Growth Factors Behind Sustained Expansion
A rising incidence of autoimmune conditions is anticipated to fuel the ankylosing spondylitis market moving ahead. These diseases encompass a wide range of conditions marked by an immune system malfunction, where the body’s defense mechanism erroneously targets and harms its own healthy cells, tissues, and organs. Conditions like ankylosing spondylitis, which are autoimmune in nature, arise when the immune system incorrectly attacks the body’s own tissues, resulting in inflammation and subsequent damage. Both genetic factors and environmental influences play a role in the onset of ankylosing spondylitis, which is an autoimmune arthritis principally impacting the spine and pelvic region. For example, data from September 2023 in the Impact of IBD Report 2023, released by the Canada-based IBD Clinical and Research Centre—an organization dedicated to enhancing the lives of individuals with Crohn’s disease and ulcerative colitis—indicated that in 2023, over 320,000 people in Canada were affected by inflammatory bowel disease (IBD), with a prevalence of 825 per 100,000. This prevalence is anticipated to grow by 2.44% each year, suggesting that by 2035, 1.1% of the population, or 470,000 Canadians, will likely be living with IBD. Consequently, the expanding occurrence of autoimmune conditions is set to stimulate future expansion within the ankylosing spondylitis market.
Ankylosing Spondylitis Market Segment Outlook: Which Categories Are Growing Fastest?
The ankylosing spondylitis market covered in this report is segmented –
1) By Treatment Type: Painkillers And Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), Disease-Modifying Anti-Rheumatic Drugs (DMARDS), Biological Therapies, Steroids, Physical Therapies, Surgery
2) By Molecule: Biologics, Biosimilar, Small Molecules
3) By Route Of Administration: Parenteral, Oral, Other Routes
4) By Application: Juveniles, Adults
5) By End User: Hospitals, Clinics
Subsegments:
1) By Painkillers And Non-Steroidal Anti-Inflammatory Drugs (NSAIDs): Over-The-Counter NSAIDs, Prescription NSAIDs
2) By Disease-Modifying Anti-Rheumatic Drugs (DMARDs): Conventional DMARDs, Targeted DMARDs
3) By Biological Therapies: TNF Inhibitors, IL-17 Inhibitors
4) By Steroids: Oral Steroids, Injectable Steroids
5) By Physical Therapies: Physiotherapy, Exercise Programs
6) By Surgery: Joint Replacement Surgery, Spinal Surgery
Ankylosing Spondylitis Market Industry Trends Fueling Future Revenue Growth
Key players within the ankylosing spondylitis market are concentrating on creating sophisticated biologic therapies, including biosimilars, aiming to improve patient accessibility, lower the cost of treatment, and offer well-known methods of administration. These biosimilars are medications that utilize the proven active components of existing reference biologics, delivering similar effectiveness and safety outcomes. As an illustration, during August 2025, Amgen Biotechnology Singapore, a biotechnology company based in Singapore, obtained approval for its adalimumab biosimilar (Amgevita), available in both a 40 mg/0.4 mL autoinjector and a 20 mg/0.2 mL prefilled syringe format. This treatment is prescribed for diminishing the indicators and manifestations in adult individuals suffering from active ankylosing spondylitis who have not responded sufficiently to traditional treatments. The benefit lies in its provision of familiar delivery methods, its utilization of a recognized active ingredient, and its presentation as a more economical alternative within the realm of biologic drugs.
Ankylosing Spondylitis Market Leading Companies And Competitive Benchmarking
Major companies operating in the ankylosing spondylitis market are Pfizer Inc., Johnson & Johnson Pvt. Ltd., Merck & Co. Inc., AbbVie Inc., Novartis AG, Bristol-Myers Squibb, Eli Lilly and Company, Gilead Sciences Inc., Boehringer Ingelheim International GmbH, Amgen Inc., Viatris Inc., Astellas Pharma Inc., AstraZeneca plc, UCB Inc., Cipla Inc., Zydus Lifesciences Limited, Celltrion Inc., Hetero Labs Ltd., Janssen Biotech Inc., Reliance Life Sciences Pvt. Ltd.
View The Full Ankylosing Spondylitis Market Report:
Ankylosing Spondylitis Market Regional Split: Which Areas Are Fueling Growth?
North America was the largest region in the ankylosing spondylitis market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the ankylosing spondylitis market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
